SCHEMBL2916499

SCHEMBL2916499

NS(=O)(=O)c1cc2ncccc2s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 15/20 0.54
CA12 O43570 4/20 0.45
CA1 P00915 4/20 0.45
CA9 Q16790 3/20 0.45
CA4 P22748 1/20 0.45
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
ALOX5 P09917 1/20 0.43
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2C Q14957 1/20 0.40
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
PLG P00747 1/20 0.39
PLAT P00750 1/20 0.39
PROC P04070 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6221023 0.83 ALOX5 (0.40) CA2CA12CA1CA9CA4
SCHEMBL29941502 0.83 ALOX5 (0.43) CA2CA12CA1CA4CA7
SCHEMBL6222812 0.83 ALOX5 (0.43) CA2CA12CA1CA4CA7
SCHEMBL8128914 0.79 POLB (0.41) CA2CDK5CDK5R1ALOX5GRIN3B
SCHEMBL10647330 0.72 CA2 (0.54) CA2CA12CA1CA9F10
SCHEMBL1107218 0.72 ALOX5 (0.48) ALOX5GRIN3BGRIN1GRIN2C
SCHEMBL5262440 0.71 AKR1B1 (0.67)
SCHEMBL28017683 0.71 ALOX5 (0.43) ALOX5GRIN3BGRIN1GRIN2CNAMPT
SCHEMBL10650164 0.71 CA2 (0.49) CA2CCNE1CDK2CDK5CDK5R1
SCHEMBL10647443 0.71 CA2 (0.53) CA2CA12CA1CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0271273-A2 Thieno-and furopyridine sulfonamides MERCK & CO. INC. (US) 1988-06-15 EP claimed
EP-1963337-B1 THIENO[2,3-b]PYRIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2010-09-01 EP disclosed
US-20100022521-A1 COMPOUNDS HANSA METALLWERKE AG (DE) 2010-01-28 US disclosed
US-20090118323-A1 ANTITUMOR BENZOYLSULFONAMIDES MADER MARY MARGARET 2009-05-07 US disclosed
EP-1963337-A1 NEW COMPOUNDS Richter Gedeon NYRT (HU) 2008-09-03 EP disclosed
EP-1565438-B1 ANTITUMOR BENZOYLSULFONAMIDES LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7282595-B2 Antitumor benzoylsulfonamides ELI LILLY AND COMPANY (US) 2007-10-16 US disclosed
WO-2007072095-A1 NEW COMPOUNDS RICHTER GEDEON NYRT. (HU) 2007-06-28 WO disclosed
US-20060106053-A1 Antitumor benzoylsulfonamides ELI LILLY AND COMPANY 2006-05-18 US disclosed
EP-1565438-A1 ANTITUMOR BENZOYLSULFONAMIDES ELI LILLY AND COMPANY (US) 2005-08-24 EP disclosed
US-6013655-A HYPOTENSIVE AGENTS; RESPIRATORY SYSTEM DIISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-01-11 US disclosed
US-6013655-A HYPOTENSIVE AGENTS; RESPIRATORY SYSTEM DIISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-01-11 US disclosed
EP-0898571-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-03-03 EP disclosed
US-5804585-A INHIBIT BINDING OF ENDOTHELIN PEPTIDE TO ENDOTHELIN RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-09-08 US disclosed
US-5804585-A INHIBIT BINDING OF ENDOTHELIN PEPTIDE TO ENDOTHELIN RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-09-08 US disclosed
WO-1997039000-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-10-23 WO disclosed
EP-0271273-A2 Thieno-and furopyridine sulfonamides MERCK & CO. INC. (US) 1988-06-15 EP disclosed
US-4731368-A Thienopyridine sulfonamides and their ophthalmological formulation MERCK & CO., INC. (US) 1988-03-15 US disclosed
US-4731368-A Thienopyridine sulfonamides and their ophthalmological formulation MERCK & CO., INC. (US) 1988-03-15 US disclosed
US-4731368-A Thienopyridine sulfonamides and their ophthalmological formulation MERCK & CO., INC. (US) 1988-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118323-A1 ANTITUMOR BENZOYLSULFONAMIDES HCCS, GLS2, GLS CA2 1594/4885CA12 122/4885CA1 428/4885
US-20060106053-A1 Antitumor benzoylsulfonamides HCCS, GLS2, GLS CA2 1594/4885CA12 122/4885CA1 428/4885
US-20100022521-A1 COMPOUNDS GRM5, GRM3, GRM1 CA2 885/4885CA12 3277/4885CA1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.